Medicine and device safety updates | 18 November 2026
- 18-11-2026
- Posted by: Eldaniz Hasanov
- Category: Regulatory Updates
This review covers 21 regulatory updates on medicine and medical device safety. It includes medicine recalls, medical device corrections and a revised adverse event reporting form.
QPPV, LQPPV and LCPPV teams can use the regulator links to assess local applicability, affected batches and follow-up. Responsibilities vary by jurisdiction.
PegLyte Powder: four lots recalled
Regulator listing: 2026-11-17. Document or action date: not separately stated. RA-82964
Health Canada reported that lots 260303, 260304, 260305 and 260306 of PegLyte Powder (DIN 00777838) may contain foreign matter. The agency asks users to check the affected lots and consult a healthcare professional before stopping use.
Official source: Health Canada
Taro-Candesartan: possible medicine mix-up
Regulator listing: 2026-11-17. Document or action date: not separately stated. RA-82965
Health Canada reported that Taro-Candesartan 8 mg tablets (DIN 02380692), lots PTG5442A and PTG5443A, may contain esomeprazole 20 mg capsules. The notice asks users to check whether their product is affected and contact a healthcare professional about any concerns.
Official source: Health Canada
ARTIS icono and pheno: possible loss of X-ray availability
Regulator listing: 2026-11-17. Document or action date: 2026-10-23. R2632274 / AX048/26/S / AX047/26/S
Siemens reported that some ARTIS icono and pheno systems with software VE40B or VE50B may fail to generate X-rays after startup or restart. The field notice describes the risk of delayed or interrupted procedures and asks sites to plan suitable alternatives for time-critical cases before the correction.
Official source: ANSM (France) · Primary attachment 1
COULTER DxH Diluent: potential platelet count bias
Regulator listing: 2026-11-17. Document or action date: 2026-11-04. R2634245 / FA-26039
Beckman Coulter reported that some diluent bottles may cause elevated residual platelet counts on certain UniCel DxH analysers. An affected bottle used without the specified daily checks could lead to overestimation of patient platelet counts. The field notice sets out individual bottle checks and covers all lot numbers of reference 628017.
Official source: ANSM (France) · Primary attachment 1
China: revised medical device adverse event reporting form
Regulator listing: 2026-11-17. Document or action date: not separately stated. 2026 revision / official card 51835
China's National Center for ADR Monitoring published a revised medical device adverse event reporting form and a Q&A after NMPA review. The form consolidates two previous forms and adds fields for investigation and corrective action, with standard IMDRF terminology. The Q&A says deployment will coincide with the upgraded reporting system. It gives no calendar date.
Official source: China’s National Center for ADR Monitoring · Primary attachment 1 · Primary attachment 2
VivaLife Easy Up Cane: recall of batch PO036280
Regulator listing: 2026-11-17. Document or action date: 2026-10-20. 41481722 / 2026/010/030/601/003
The field notice linked by MHRA describes a recall of VivaLife Easy Up Cane batch PO036280. The top section may separate when the cane is lifted, creating a fall risk. The notice tells users of the affected batch to stop use and follow the return instructions.
Official source: MHRA (United Kingdom) · Primary attachment 1
Raz shower commode chairs: replacement of specified seats
Regulator listing: 2026-11-17. Document or action date: 2026-11-04. 41422412 / 2611-02
Raz Design's field notice linked by MHRA states that affected moulded and VFI seats on specified Raz shower commode chair models may break and cause injury. The corrective action provides for replacement of the affected seats. The notice lists the models and seat catalogue numbers.
Official source: MHRA (United Kingdom) · Primary attachment 1
Ibuprofen Velfarm: recall of batch 301025
Regulator listing: 2026-11-17. Document or action date: 2026-11-17. 01И-1343/26
Roszdravnadzor reported that the manufacturer recalled Ibuprofen Velfarm 400 mg tablets, batch 301025, after a consignment failed the dissolution requirement. The letter requests confirmation of removal and measures to address the risk of harm.
Official source: Roszdravnadzor (Russia) · Primary attachment 1
Pyridoxine: withdrawal of specified consignments
Regulator listing: 2026-11-16. Document or action date: 2026-11-16. 01И-1329/26
Roszdravnadzor stopped circulation of specified consignments of pyridoxine 50 mg/mL injection from batches 340925 and 401225 after finding non-compliance with shelf-life requirements. The letter calls for removal and destruction of the identified consignments and measures to address the risk of harm.
Official source: Roszdravnadzor (Russia) · Primary attachment 1
ASK-cardio: manufacturer recall of batch 050060225
Regulator listing: 2026-11-16. Document or action date: 2026-11-16. 01И-1332/26
Roszdravnadzor reported a manufacturer recall of ASK-cardio 100 mg gastro-resistant tablets, batch 050060225, following labelling non-compliance. The new letter follows the October action on an identified consignment of the same batch and requests information about removal of the stated batch.
Official source: Roszdravnadzor (Russia) · Primary attachment 1
BD Connecta: hospital recall of selected lots
First observed: 2026-11-18. Document or action date: 2026-11-16. RC-2026-RN-00940-1
TGA records a Class II hospital recall of selected lots. Tubing may separate from the connector, interrupting infusion and creating leakage, infection or air embolism risks. The notice calls for replacement with unaffected products.
Official source: TGA (Australia)
Caruso’s Immune Aid: Class I consumer recall
First observed: 2026-11-18. Document or action date: 2026-11-16. RC-2026-RN-00924-1
TGA records a Class I consumer recall of batch Q01192, expiry August 2027. The action applies to this product within the known Andrographis anaphylaxis concern. The notice tells consumers not to use the affected product and explains return options.
Official source: TGA (Australia)
Injectable Cipla Hydrocortisone: recall after glass fragment report
First observed: 2026-11-18. Document or action date: 2026-11-16. RC-2026-RN-00935-1
TGA records a Class II recall of batch HY0102501A of hydrocortisone sodium succinate 100 mg powder for injection following a report of a glass fragment in a vial. The notice requests quarantine of the batch and states that smaller fragments could cause injury if inadvertently injected.
Official source: TGA (Australia)
LP(a) Calibrator Series: recall of affected calibrators
First observed: 2026-11-18. Document or action date: 2026-11-16. RC-2026-RN-00943-1
TGA records a Class II hospital recall of specified lots of LP(a) calibrators. Cloudy vials may alter calibration and patient results even when calibration passes. The notice asks laboratories to stop using the affected sets and assess previous results with their medical director.
Official source: TGA (Australia)
Polaris surgical lights: corrective replacement of light heads
First observed: 2026-11-18. Document or action date: 2026-11-16. RC-2026-RN-00932-1
TGA records a Class II product correction. A signal interruption can leave illumination active in safe mode while making the controls unavailable during surgery. The notice describes a planned replacement of affected light heads and the option to switch to redundant lighting if the fault occurs.
Official source: TGA (Australia)
Streptex: recall of lot 6416336 after false-negative concern
First observed: 2026-11-18. Document or action date: 2026-11-16. RC-2026-RN-00925-1
TGA records a Class III hospital recall of Streptex lot 6416336. A reagent interaction can cause false-negative reactions. The notice describes the clinical risk as low and asks sites to quarantine affected stock and assess any need to review prior results.
Official source: TGA (Australia)
Orencia: update to the patient card
Regulator listing: 2026-11-17. Document or action date: 2026-11-12. EMA/PSUR/0000344377 / PSUSA/00000013/202512
The EMA procedural record describes an update to the abatacept patient card, an additional risk minimisation measure, following a periodic safety review. The European Commission decision is dated 12 November. The update affects Annex II and labelling.
Official source: EMA (European Union) · Primary attachment 1
Kyinsu: product information now includes the NAION warning
Regulator listing: 2026-11-16. Document or action date: 2026-11-16. EMA/VR/0000380695
The EMA procedural record confirms that Kyinsu's product information and patient leaflet now include a warning about non-arteritic anterior ischaemic optic neuropathy (NAION). The change implements findings from a previous periodic safety review of other semaglutide-containing medicines.
Official source: EMA (European Union) · Primary attachment 1
Leflunomide ratiopharm: myositis and rhabdomyolysis warning
Regulator listing: 2026-11-16. Document or action date: 2026-11-16. EMA/VR/0000383958
The EMA procedural record confirms an update to section 4.4 of the summary of product characteristics and section 2 of the patient leaflet to include a warning on myositis and rhabdomyolysis. The update aligns this product information with the cumulative safety review for Arava.
Official source: EMA (European Union) · Primary attachment 1
Oncaspar: changes to the risk management plan and study deadlines
Regulator listing: 2026-11-16. Document or action date: 2026-11-16. EMA/VR/0000382985 / PSUSA/000110457/202507
The EMA procedural record describes a change to the Oncaspar risk management plan after periodic safety review. It removes 'embryotoxicity and teratogenicity' from the plan's list of safety concerns and updates milestones for the CAALL-F01 study. Consult the approved product information for advice on use in pregnancy.
Official source: EMA (European Union) · Primary attachment 1
Uzbekistan: updated safety criteria for nonprescription classification
Regulator listing: 2026-11-16. Document or action date: 2026-10-22. Order No. 30 / 3430-2
The Centre for Pharmaceutical Product Safety reported revised criteria for nonprescription classification, including safe use without continuous professional supervision, low risks of misuse and overdose, and assessment of the benefit-risk balance for combination medicines. The Centre says it can revisit classification using new safety or efficacy data and pharmacovigilance results. Order No. 30 was registered on 12 November and published on 13 November. Most provisions take effect on 14 February 2027. The fifth subparagraph of paragraph 1 of the annex takes effect on 13 January 2027.
Official source: Uzbekistan’s Centre for Pharmaceutical Product Safety · Primary attachment 1
Disclaimer. This material is provided solely for information and pharmacovigilance purposes, based on official communications issued by Health Canada, ANSM (France), China’s National Center for ADR Monitoring, MHRA (United Kingdom), Roszdravnadzor (Russia), TGA (Australia), EMA (European Union), Uzbekistan’s Centre for Pharmaceutical Product Safety and current as of 18 November 2026. It is not medical or legal advice, does not replace the official source, and does not imply wrongdoing by the manufacturer/marketing authorisation holder or a quality concern affecting the company's entire product portfolio. Company and product names are used only to identify the official material accurately. Decisions should be based on the primary source, the regulator's instructions and the approved product information.